ReviewToxins2021
The Search for Natural and Synthetic Inhibitors That Would Complement Antivenoms as Therapeutics for Snakebite Envenoming.
Review in Toxins, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 42 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
42 citing papers in PubMed, 1 synthesis or guideline pooled it.
- A review and in silico screening of plant-derived snake venom/toxin inhibitors: ADMET, drug-likeness, and medicinal chemistry profiling.PLoS neglected tropical diseases · 2025Pooled it
- Exploiting the Property of a New Series of 1,2,3-Triazole Compounds as Inhibitors of In Vivo and In Vitro Toxic Effects Caused byTropical medicine and infectious disease · 2026Article
- Engineering Antivenom: Research Progress and Future Directions in Snakebite Envenoming Therapy.Annals of the New York Academy of Sciences · 2026Review
- Article
- Targeting Key Enzymatic Snake Venom Proteins Using Repurposed Small Molecule Inhibitors: Emerging Adjuncts to Antivenom Therapy.International journal of molecular sciences · 2026Review
- Venom variation and the future of antivenom design: Integrating population venomics, evolutionary toxinology, and precision therapeutics.Toxicon: X · 2026Review
- Identification of DC-174 as a Novel Hydroxamic Precandidate for the Development of an Oral Snakebite Treatment.Journal of medicinal chemistry · 2026Article
- Inhibitory effects of 6-O-palmitoyl-L-ascorbic acid (ASC16) on the enzymatic activity of Bothrops alternatus venom.Archives of toxicology · 2025Article
- Hematological and coagulation alterations and splenic response following Macrovipera lebetina obtusa envenomation: Evaluation of ovine-derived experimental antivenom.PLoS neglected tropical diseases · 2025Article
- Snake Venom Compounds: A New Frontier in the Battle Against Antibiotic-Resistant Infections.Toxins · 2025Review
- Bioinformatics-Guided Identification and Quantification of Biomarkers of Crotalus atrox Envenoming and Its Neutralization by Antivenom.Molecular & cellular proteomics : MCP · 2025Article
- Plant-Derived Lapachol Analogs as Selective Metalloprotease Inhibitors AgainstInternational journal of molecular sciences · 2025Review
- Article
- Enhancing the Bothropic Antivenom through a Reverse Antivenomics Approach.Journal of proteome research · 2025Article
- A comprehensive review on recent advances in the use of ethnomedicinal plants and their metabolites in snake bite treatment.Frontiers in pharmacology · 2025Review
- Myotoxicity of Crotoxin on C2C12 Myoblasts and its Inhibition byCurrent protein & peptide science · 2025Article
- Article
- Therapeutic itineraries of snakebite victims and antivenom access in southern Mexico.PLoS neglected tropical diseases · 2024Article
- Characterization of plant produced VBiotechnology reports (Amsterdam, Netherlands) · 2024Article
- Development of a membrane-disruption assay using phospholipid vesicles as a proxy for the detection of cellular membrane degradation.Toxicon: X · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
A global strategy, under the coordination of the World Health Organization, is being unfolded to reduce the impact of snakebite envenoming. One of the pillars of this strategy is to ensure safe and effective treatments. The mainstay in the therapy of snakebite envenoming is the administration of animal-derived antivenoms. In addition, new therapeutic options are being explored, including recombinant antibodies and natural and synthetic toxin inhibitors. In this review, snake venom toxins are classified in terms of their abundance and toxicity, and priority actions are being proposed in the search for snake venom metalloproteinase (SVMP), phospholipase A
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.